Addus HomeCare Corporation (ADUS) saw its stock plummet 5.40% in Tuesday's trading session, despite receiving a target price increase from Barclays. The conflicting signals from the investment bank appear to have spooked investors, leading to a significant sell-off.

Barclays raised its target price for Addus HomeCare from $111 to $117, which would typically be seen as a positive development. However, the investment bank simultaneously maintained its Underweight rating on the stock. This maintenance of a bearish stance seems to have overshadowed the increased price target in investors' minds.

The market's strong negative reaction suggests that investors are placing more weight on the maintained Underweight rating than on the higher target price. This could indicate ongoing concerns about Addus HomeCare's fundamental performance or its position within the competitive landscape of the home healthcare sector. As the trading session progressed, the selling pressure intensified, resulting in the substantial 5.40% drop by the end of the day.